Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery shows potential in preventing peritoneal metastases in high-risk colorectal cancer. Recent randomized controlled trials, including Hipect4, demonstrate improved locoregional disease control with HIPEC, without an increase in complications. Despite negative results in trials like Prophylochip and Colopec, the methodology and patient selection criteria provide valuable insights. Ongoing trials aim to further explore the role of HIPEC in advanced colorectal cancer prevention.
Review by Sun BJ, Daniel SK and Lee B in J Clin Med